Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular Inc. demonstrated notable financial performance, with gross margin expanding by 110 basis points year-over-year to 70%, attributed to increased average selling prices, manufacturing efficiencies, and a favorable product mix. Revenue for the quarter rose by 15%, driven by strong contributions from the catheter category and significant growth in international sales, alongside an operating income increase of 12% to $16.1 million, resulting in an operating margin of 25%. The company anticipates continued momentum, projecting a year-end gross margin of 69.7% and operating income growth of 17%, reinforcing a positive outlook for strong sales growth and expanding margins.

Bears say

LeMaitre Vascular is facing a declining operating margin, expected to decrease from 25% to 24% due to seasonal variations, indicating potential challenges in maintaining profitability. The reduction in the target number of sales representatives from 170 to 165 could signal difficulties in driving sales growth, reflecting a cautious outlook on revenue generation. Additionally, a notable decrease in R&D spending to 6% of revenue highlights concerns about the firm's commitment to innovation amidst competitive pressures and regulatory challenges, which could adversely affect future financial performance.

LeMaitre Vascular (LMAT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 6 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.